Key Points Interested in Satellos Bioscience Inc.? Here are five stocks we like better. Satellos Bioscience said its SAT-3247 ...

All four participants showed a decline in fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to ...

Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy (DMD) drug candidate is active in adults, ...

"In many countries, health insurance changes when DMD men are no longer seen in a specialized pediatric center. This impacts massively on the quality of care they receive. For this reason, many DMD ...

A drug from the same family licensed for use in patients with Duchenne muscular dystrophy and blood cancer could transform ...

Edgewise Therapeutics Inc EWTX released 12-month topline results from the ARCH study, an open-label, single-center study assessing EDG-5506 in adults with Becker Muscular Dystrophy (BMD). EDG-5506 is ...

Many more adults with Duchenne muscular dystrophy (DMD) are living longer thanks to improvements in treatment, however international standards of care have not yet fully addressed the complex needs of ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the ...

– Significant decreases were observed in circulating levels of creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), biomarkers associated with skeletal muscle damage – – Sevasemten was ...

Burn Boot Camp totals $3.8 million in donations to MDA’s mission since 2016. Burn Boot Camp and Muscular Dystrophy ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the ...